YMAB

Y mAbs Therapeutics (YMAB)

Y mAbs Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:YMAB

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/14	10 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/14	10 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/14	10 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/14	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/12	08 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/12	08 : 53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/11	05 : 59	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/11	05 : 44	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/07	20 : 05	GlobeNewswire Inc.	Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/05	20 : 05	GlobeNewswire Inc.	Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/01	21 : 15	GlobeNewswire Inc.	Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/01	21 : 05	GlobeNewswire Inc.	Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/01	10 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/06/01	10 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/05/24	07 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/05/22	05 : 42	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/05/08	05 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/05/08	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/05/08	05 : 05	GlobeNewswire Inc.	Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/04/26	20 : 05	GlobeNewswire Inc.	Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/04/26	05 : 05	GlobeNewswire Inc.	Y-mAbs to Present at 2024 ASCO Annual Meeting	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/03/14	22 : 05	GlobeNewswire Inc.	Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/03/08	07 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/03/08	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/03/08	06 : 59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/03/07	06 : 49	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/03/07	06 : 40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/03/06	09 : 05	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/03/04	21 : 30	GlobeNewswire Inc.	Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors	NASDAQ:YMAB	Y mAbs Therapeutics Inc
2024/03/04	20 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:YMAB	Y mAbs Therapeutics Inc